CXCR3 and neoplasm: Based on insights from mechanistic studies that showed chemokine receptors CXCR3, CCR2, and CCR5 are critical for T cell trafficking to the tumor site [77], several preclinical studies have investigated strategies that increased chemokine signaling in CAR-Ts.